A legal entity created on a voluntary basis and engaged in a certain business, company can operate in different market and counties. A company size is measured on the basis of its market value, sales, assets or profits. As a rule, companies are represented by the following types: be private, public, government, unlimited, foreign, producer, to name a few. Typical departments found in almost any company comprise but are not limited to production, customer services, marketing, human resources, finance, to name a few.
Exxon Mobil, JPMorgan Chase, Shell, Apple, Royal Dutch Shell and Toyota Motor are amidst the globe’s largest and most influential companies, with most of them active the world over.
This Catalogue’s research reports cover companies involved in various business activities, be it production, sales, marketing, etc. The reports contain information on companies’ activities, historical development, key executives, departments, product offerings. SWOT analyses, data on market share, marketing strategies, the most recent activities within the industry, acquisitions, strategic partnerships and alliances are included in the research reports.
Publications found:
193,061
Sort by:
SUN PHARMA – Outperform, Balance Sheet Leveraging At Play
US$ 140.00
... complex generics to drive growth. In other words, balance sheet would remain the biggest growth driver, both for ... generics are dwindling. DUSA acquisition looks very attractive for Sun Pharma due to (1) DUSA is acquired at a trailing EV / Operating ... of Rs.795 and reiterate our Outperform rating on the stock.
November 2012
7 pages
AMGEN- Launched Products + Geographical Expansion Should Sustain the Growth Momentum
US$ 140.00
... Biosimilars opportunity. AMGN is trading below the NPV of its marketed products + net debt ($92.0/s) and in light of upcoming catalysts, we ... more details on pipeline products, please read our report released on 8th Nov. 2012, titled, “Amgen - Launched Products + Geographical Expansion Should Sustain the ...
November 2012
7 pages
BIOGEN IDEC - Diversification and Strong Foothold in MS to Reign
US$ 90.00
We continue to like Biogen Idec (BIIB) as next year is also going to be eventful: Approval and launch of BG-12 ( ... , please read our report released on 7th Nov. 2012, titled, “Biogen Idec - Diversification and Strong Foothold in MS to Reign”.
November 2012
4 pages
PFIZER, Xeljanz (tofacitinib) approved for RA, but we see limited potential
US$ 90.00
Pfizer has been granted FDA approval for Xeljanz (tofacitinib) 5 mg twice daily for the ... fortnightly (subcutaneous) or much less frequent than tofacitinib. Besides no differentiation from a clinical perspective ... alpha therapy. Pfizer is also planning to discuss with FDA for the role of tofacitinib as first-line ...
November 2012
2 pages
Comparative Strategic Factor Analysis Summary (SFAS) Framework Analysis & Strategic Outlook for 2013 - World's 7 Leading Construction Equipment Manufacturers - Caterpillar, Komatsu, Volvo, CNH, Hitachi, Sandvik & Terex
US$ 1,275.00
... structure, characteristics, developments, strategies, initiatives & plans of these 7 key Global construction equipment manufacturing companies through a Strategic Factor Analysis Summary (SFAS) framework against the backdrop of an evolving industry landscape & market situation; marked by a significant ...
November 2012
100 pages
